Actively Recruiting
Early Feasibility Study of the Nyra CARLEN System for Treatment of Moderate-to-Severe Functional Mitral Valve Regurgitation
Led by Nyra Medical, Inc. · Updated on 2026-07-28
30
Participants Needed
3
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and performance of the CARLEN System in patients with symptomatic, moderate-to-severe or severe functional mitral valve regurgitation MR 3. This early feasibility study focuses on individuals who continue to experience symptoms despite receiving the best available medical therapy, aiming to explore a new treatment option for this heart condition. Participants will receive the CARLEN System, a device designed for transcatheter mitral valve repair. The study is conducted as a single-group trial where all participants will undergo treatment with this device. The procedure and follow-up care are carefully monitored to assess device performance and safety. During the study, participants will be asked to attend follow-up visits to monitor their health and the devices effects. Researchers will collect data on outcomes such as safety and the primary endpoint measured 30 days after the procedure. The study involves ongoing assessments to track how well the device works and to ensure participant safety throughout the trial period, which may last up to several years.
CONDITIONS
Brief Title
Early Feasibility Study (EFS) of the Nyra Cardiac Leaflet Enhancer (CARLEN) System
Research Team
J
Jennifer Mischke, VP of Regulatory and Clinical
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here